Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer
Disease area: Thoracic oncology

Abstract

Background: The type I interferon receptor subunit, interferon (-alpha, -beta, and –omega) receptor 2 (IFNAR2), has been reported to be overexpressed in several malignancies, primarily adenocarcinomas (ADCs). However, the biological significance of IFNAR2 in human lung cancer has not yet been studied.
Methods: Immunohistochemical analysis of 113 surgically resected non-small cell lung cancer specimens was performed. Serum concentrations of IFNAR2 were also determined by an enzyme-linked immunosorbent assay in 157 lung cancer patients and 164 healthy volunteers.
Results: IFNAR2 overexpression was observed in all histological types of lung cancers examined. Furthermore, strong IFNAR2 expression was associated with shorter progression-free survival (PFS) and overall survival (OS) (p < 0.0001 and p =0.0110, respectively) in non-small cell lung cancer patients. Multivariate analyses confirmed its independent prognostic value for PFS and OS (p < 0.0001 and p= 0.0222, respectively). IFNAR2 serum levels were also significantly higher in lung cancer patients than in healthy volunteers (p < 0.0001).
Conclusions: IFNAR2 overexpression was observed in various histological types of lung cancers, and appears to be associated with lung cancers that behave aggressively. The results of this study strongly support the potential of IFNAR2 as a diagnostic and prognostic biomarker for lung cancer.

Rating:

Share or cite this content

Citations should be made in the following way:
N. Ishikawa, N. Hattori, S. Tanaka, Y. Horimasu, A. Yokoyama, N. Kohno (Hiroshima, Nankoku, Japan). Interferon (-alpha, -beta, and -omega) receptor 2 (IFNAR2) is a prognostic biomarker for lung cancer. Eur Respir J 2011; 38: Suppl. 55, 4504

Member's Comments

No comment yet.

Related content which might interest you: Soluble interleukin 2 receptor ( sIL-2R ) during chemotherapy of the lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 Interleukin -18 (IL-18) and tumor necrosis factor (TNF) in sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002 The levels of osteoprotegerin (OPG), interleukin 18 (IL-18) and soluble interleukin 2 receptor (sIL-2R) in serum during chemotherapy of lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004 Lung expression of interleukin-13 (IL-13) and interferon gamma (IFNg) in emphysema in human Source: Eur Respir J 2002; 20: Suppl. 38, 584s Year: 2002 Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interleukin (IL) 1-beta in small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 Upregulation of interleukin 13 receptor alpha 2 (IL-13RA2) expression in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 267s Year: 2005 The haplotypes of interleukin 10 but not that of tumour necrosis factor alpha/lymphotoxin alpha and interleukin 1 cluster are associated with susceptibility for COPD Source: Eur Respir J 2005; 26: Suppl. 49, 105s Year: 2005 Changes in the quantity of 1b-interleukin (IL-1b), tumor necrosis factor-a (TNF-a) and interferon-g (IF-g) in evaluation of the effectiveness of treatment of tuberculosis by DOTS Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004 Expression of transforming growth factor β (TGFβ) receptor, CD105, is declined in Th1 interstitial lung diseases (ILDs) Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Hypoxia inducible factor-1 alpha (HIF-1 alpha) expression was correlated with the survival in patients with small cell lung cancer (SCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Relationship between level of transforming growth factor beta 1 (TGF beta 1) and serum amyloid A in COPD patients Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Does tumour necrosis factor-alpha (TNF-alpha) induced by lipopolysaccharide have a positive feedback effect on the up-regulation of interleukin-8 (IL-8) messenger RNA by monocytes from COPD patients? Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Mould exposure at home relates to inflammatory markers in blood Source: Eur Respir J 2003; 21: 317-322 Year: 2003 TGF-β 1 suppresses IRF-1 expression in pulmonary fibroblasts and modulates its induction by IFN α and IFN γ Source: Annual Congress 2011 - Lung cell injury and repair Year: 2011 Interferon gamma (IFN?) pathway deficiency and severe NTM disease Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease Year: 2021 Transforming growth factor beta (TGF-ß) pathway activation by IPF fibroblast-derived soluble factors is mediated by IL-6 trans-signaling Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 Interleukin-18, interleukin-12, interferon γ and interleukin-18 receptor expression is decreased in the recovery phase of pulmonary sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 366s Year: 2001 The Role of Interleukin (IL) - 10 in a murine model of lung adenocarcinoma (ADC) Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench Year: 2017 Late-breaking abstract: Serum concentrations of new factors (IL-20, galectin 3, IL-29 and IL-33) involved in angiogenesis in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer Year: 2011 Interleukin-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction Source: Eur Respir J 2005; 26: Suppl. 49, 2s Year: 2005